Camber Specialty Capabilities
In 2022, Hetero and Camber Pharmaceuticals established Camber Specialty in response to the growing demand for high-quality, low-cost specialty medications supporting hospitals, clinics, oncology treatment centers, government, and other institutional customers.
Learn more about Camber Specialty in this short video.
Recent articles
- Camber Launches Eletriptan Hydrobromide Tablets
- Camber Launches Abacavir and Lamivudine Tablets, USP
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
